Back to all Oryzon Genomics S.A. press releases
Oryzon Genomics S.A.
- BME:ORY
- OTC PINK:ORYZF
Oryzon enrols first patient in Phase Ib RESTORE trial of iadademstat for sickle cell disease
Published
At a glance
- Company
- Oryzon Genomics S.A.
- Listings
- BME:ORY, OTC PINK:ORYZF
- Announcement type
- Operational update
- Published
- Source announcement
- oryzon.com
FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices
Announcement Summary
Oryzon Genomics, S.A. (Ticker: ORY) announced an update to RESTORE, its iadademstat trial for adults with sickle cell disease.
- On November 3, 2025, the company announced that the first patient had been enrolled in RESTORE, a multicenter, open-label Phase Ib trial.
- The study aims to enroll approximately 40 adult patients across several sites in Spain.
- The study is designed to evaluate iadademstat’s safety and tolerability in adults with sickle cell disease.
- RESTORE is designed to establish the recommended Phase 2 dose, or RP2D, for this indication.
- The study is designed to evaluate iadademstat’s effect on inducing fetal hemoglobin, or HbF, expression.
The company expects initial insights within the next few months. Nearly 200 patients have been treated with iadademstat to date.
Investor FAQs
Source announcement
- Company
- Oryzon Genomics S.A.
- Title
- ORYZON announces First‑Patient‑In (FPI) in RESTORE Phase Ib trial of iadademstat in sickle cell disease
- Published
- Source site
- oryzon.com
Read the source announcement on oryzon.com
FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.
Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.
Read the original press release
Full text as published, unedited.